# Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma

> **NCT03728465** · PHASE2 · TERMINATED · sponsor: **University Hospital Tuebingen** · enrollment: 6 (actual)

## Conditions studied

- Metastatic Melanoma
- Brain Metastases

## Interventions

- **BIOLOGICAL:** Nivolumab
- **BIOLOGICAL:** Ipilimumab

## Key facts

- **NCT ID:** NCT03728465
- **Lead sponsor:** University Hospital Tuebingen
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-10
- **Primary completion:** 2021-01-01
- **Final completion:** 2021-01-01
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Lack of patients
- **Last updated:** 2021-02-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03728465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03728465, "Evaluation of Safety and Efficacy of Patients With Four and More Symptomatic Brain Metastases of Melanoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03728465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*